Bioventix (LON:BVXP) Shares Cross Above 50 Day Moving Average – Time to Sell?

Posted by Casey Walker on May 6th, 2026

Bioventix PLC (LON:BVXP – Get Free Report)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 1,604.23 and traded as high as GBX 1,750. Bioventix shares last traded at GBX 1,660, with a volume of 9,220 shares traded.

Bioventix Trading Down 2.9%

The company’s 50 day moving average is GBX 1,604.23 and its 200-day moving average is GBX 1,803.34. The company has a market capitalization of £86.21 million, a P/E ratio of 11.74 and a beta of 0.48.

Bioventix (LON:BVXP – Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share (EPS) for the quarter. The company had revenue of GBX 615.88 billion during the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. Analysts predict that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.

Insider Buying and Selling at Bioventix

In other news, insider Ian James Nicholson acquired 1,000 shares of Bioventix stock in a transaction on Friday, April 10th. The stock was acquired at an average cost of GBX 1,848 per share, for a total transaction of £18,480. Also, insider Bruce Hiscock acquired 66 shares of Bioventix stock in a transaction on Monday, April 27th. The shares were purchased at an average price of GBX 1,679 per share, with a total value of £1,108.14. In the last ninety days, insiders bought 2,131 shares of company stock worth $3,927,999. 6.16% of the stock is owned by corporate insiders.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.